You are here

Biomarker Matrix for Genotoxicity Mode of Action

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44ES024039-02
Agency Tracking Number: R44ES024039
Amount: $976,469.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIEHS
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-02-01
Award End Date (Contract End Date): 2017-01-31
Small Business Information
3500 WINTON PL
Rochester, NY 14623-2860
United States
DUNS: 085992055
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 STEPHEN DERTINGER
 (585) 442-0930
 sdertinger@litronlabs.com
Business Contact
 CAROL TOMETSKO
Phone: (585) 442-0930
Email: caroltomet@aol.com
Research Institution
N/A
Abstract

DESCRIPTION provided by applicant It is well recognized that current batteries of genetic toxicology assays exhibit relatively high sensitivity meaning they effectively identify genotoxic carcinogens However a critical deficiency with current approaches exists namely the specificity of the in vitro mammalian cell genotoxicity tests is low as they yield a high incidenc of positive results that do not have in vivo relevance so called andquot misleadingandquot or andquot irrelevantandquot positives This high incidence of irrelevant in vitro positive results leads to extensive and costy additional testing often with whole animal models or else abandonment of potentially valuable products We will address this major problem with current in vitro mammalian cell genetic toxicity assays by developing commercial kits that enable an automated testing strategy that exhibits both high sensitivity and specificity This system will categorize positive results according to the predominant mode of genotoxic activity and importantly will reliably identify irrelevant mode s of action that are likely to be nonoperational in vivo A secondary objective of
the proposed work is the development of methods for characterizing clastogens That is we will develop tools that elucidate whether clastogenic activity is the result of DNA reactivity or whether it is mediated by an indirect mechanism PUBLIC HEALTH RELEVANCE Sub lethal DNA damage that cannot be faithfully repaired results in gene mutation and or chromosomal aberrations and these effects are known to contribute to carcinogenesis There is also emerging evidence that DNA damage contributes to germline genetic disorders and other disease sequelae for instance atherosclerosis Thus there is an important need for sensitive and specific assays to evaluate chemicals for genotoxic potential Furthermore in cases when genotoxic potential has been determined more efficient means of elucidating genotoxic mode of action would be useful for understanding human health risks

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government